3386 — Cosmo Bio Co Income Statement
0.000.00%
Last trade - 00:00
- ¥6bn
- ¥4bn
- ¥9bn
- 77
- 59
- 59
- 77
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
Standards: | JAS | JAS | JAS | JAS | JAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 7,590 | 8,092 | 9,231 | 9,553 | 9,340 |
Cost of Revenue | |||||
Gross Profit | 2,880 | 3,152 | 3,659 | 3,441 | 3,250 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 7,266 | 7,340 | 8,183 | 8,766 | 8,794 |
Operating Profit | 324 | 752 | 1,048 | 787 | 546 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 388 | 1,008 | 1,099 | 790 | 653 |
Provision for Income Taxes | |||||
Net Income After Taxes | 246 | 701 | 769 | 552 | 462 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 238 | 674 | 738 | 517 | 443 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 237 | 674 | 737 | 517 | 442 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 48.6 | 114 | 127 | 92.5 | 72.6 |
Dividends per Share |